Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04644211 · ClinicalTrials.gov registry record · Phase 2
Ruxolitinib in Thrombocythemia and Polycythemia Vera
A Phase 2 study of Polycythemia Vera and Essential Thrombocythemia, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 4
- Study locations
NCT04644211: Recruiting Phase 2 study of Polycythemia Vera and Essential Thrombocythemia, sponsored by Massachusetts General Hospital.
NCT04644211 is a Phase 2 study of Polycythemia Vera and Essential Thrombocythemia that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 60 participants, below the 338-participant average among 22 other Polycythemia Vera trials with a reported enrollment target (82% lower). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04644211, a Phase 2 study of Polycythemia Vera and Essential Thrombocythemia, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 4
- Study locations
Study Summary
This research is being done to see if the drug ruxolitinib is effective in reducing the symptoms caused by low-risk essential thrombocythemia (ET) and polycythemia vera (PV). \- This research study involves the study drug Ruxolitinib.
Primary Outcome
Percentage of patients with \>50% change in Myeloproliferative Neoplasm Symptom Assessment Total Symptom Score (MPN-SAF TSS), which has use in major clinical trials and as symptom assessment in all patients in clinical practice. Modeling has established baseline MPN-SAF TSS cut-off scores (total MPN-SAF TSS \>20 or an individual component score \>5) at which symptomatic treatment would be significantly beneficial
Conditions Studied
Interventions
- DRUG Ruxolitinib
Study Locations (4)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth-Israel Deaconess Medical Center - Boston
- Dana Farber Cancer Institute - Boston
- Massachusetts General North Shore Cancer Center - Danvers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-03-21 |
| Est. Completion | 2034-07 |
| Phase | Phase 2 |
What NCT04644211 shows while recruiting
NCT04644211 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 338-participant average among 22 other Polycythemia Vera trials with a reported enrollment target (82% lower).
The record links to 2 conditions, with Polycythemia Vera appearing as the primary indexed condition, and to 1 intervention - of which Ruxolitinib is the first listed.
NCT04644211 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04644211 about?
NCT04644211 is a clinical study titled "Ruxolitinib in Thrombocythemia and Polycythemia Vera". This research is being done to see if the drug ruxolitinib is effective in reducing the symptoms caused by low-risk essential thrombocythemia (ET) and polycythemia vera (PV). \- This research study involves the study drug Ruxolitinib.
What is the current status of trial NCT04644211?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2022-03-21. Estimated completion is 2034-07.
What conditions does trial NCT04644211 study?
This clinical trial studies the following conditions: Polycythemia Vera, Essential Thrombocythemia.
What interventions are being tested in trial NCT04644211?
The interventions under investigation include: Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT04644211?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04644211 being conducted?
This trial has 4 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Polycythemia Vera
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04644211's enrollment target sits among peer trials
60 11th of 22 higher than 11 of 22 other Polycythemia Vera trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Polycythemia Vera trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
RECRUITING · Phase 2
-
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
RECRUITING · Phase 2
-
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
RECRUITING · Phase 2
-
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
ACTIVE NOT RECRUITING · Phase 2
-
IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)
ACTIVE NOT RECRUITING · Phase 2
-
Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI